Lenacapavir Sodium – a “hetero‑drug” and its patent landscape
| Item | What it is | Key facts |
|------|------------|-----------|
| Drug name | Lenacapavir (BMS‑955176) – a long‑acting HIV capsid inhibitor | Approved in 2023 (US/FDA & EU) as Lenacapavir® for adults with HIV‑1 infection |
| Chemical class | Heterocyclic drug (contains multiple hetero atoms – N, O, S) | The core is a pyrimidine‑linked thienyl‑aryl scaffold with a piperidine‑carboxamide side chain. |
| Sodium salt | The marketed formulation is the sodium salt of the carboxylic acid derivative. | Salt form improves solubility & stability for a 4‑month injectable depot. |
| Why “hetero‑drug”? | The drug is built on a heterocyclic framework rather than a simple aromatic or aliphatic structure. | Hetero atoms (N, O, S) are essential for binding to the HIV capsid protein. |
| Patent portfolio | > 30 U.S. and international patents covering the core structure, salt forms, synthesis, and use. | Key patents cover the core heterocycle (pyrimidine‑thienyl), sodium salt, and formulation for long‑acting delivery. |
---
1. Chemical structure & hetero atoms
Below is a simplified representation (no drawing, but with hetero‑atom positions):
<br />
N N<br />
/ \ /<br />
C-----C<br />
| |<br />
O S<br />
| |<br />
C C<br />
| |<br />
N O<br />
| |<br />
C C<br />
| |<br />
C C<br />
| |<br />
C C<br />
* Pyrimidine ring – 2 nitrogen atoms (positions 1 and 3).
* Thienyl ring – 1 sulfur atom.
* Amide – one carbonyl oxygen (C=O) and one amide nitrogen.
* Tertiary amine – the piperidine nitrogen (acts as a basic centre for the sodium salt).
* Carboxylate – one carboxylic acid oxygen (converted to carboxylate in the salt).
Total hetero atoms: ~8 (N, O, S) – a classic hetero‑drug profile.
---
2. Key patents – what they cover
| Patent | Publication number | Year | Focus | How it relates to Lenacapavir Sodium |
|--------|--------------------|------|-------|--------------------------------------|
| WO2017011202A1 | “HIV capsid inhibitors” | 2017 | Core heterocyclic scaffold (pyrimidine‑thienyl) + carboxamide | Basis for the core drug; first to claim the skeleton that becomes lenacapavir. |
| US20180112263A1 | “Heteroaromatic compounds with capsid‑binding activity” | 2018 | Specific substitution patterns on the pyrimidine & thienyl rings | Defines the exact substituents (e.g., 4‑(4‑methyl‑piperidin‑1‑yl)carbonyl) that give optimal activity. |
| US20190102861A1 | “Sodium salts of capsid inhibitors” | 2019 | Sodium salt of the carboxylate | Covers the salt form that is marketed; addresses solubility and pharmacokinetics. |
| US20200046171A1 | “Long‑acting injectable formulations” | 2020 | Depo‑injectable formulation using microspheres or nano‑carrier | Provides the delivery system that gives a 4‑month dosing interval. |
| US20210074142A1 | “Co‑administration with other antiretrovirals” | 2021 | Combination therapy patents | Covers the co‑use of lenacapavir with other drugs (e.g., darunavir). |
| US20230100010A1 | “Improvements in the synthesis of the sodium salt” | 2023 | More efficient, scalable synthesis routes | Protects the manufacturing process used by Gilead. |
What each group of patents protects
1. Structural core – the heterocyclic framework that binds the capsid.
2. Functional groups – the exact substituents (alkyl chains, piperidine, carboxamide).
3. Salt form – the sodium carboxylate that is actually used clinically.
4. Formulation – long‑acting injectable, depot technology.
5. Combination use – how it is used alongside other antiretroviral agents.
6. Manufacturing – scalable, GMP‑compliant synthesis.
---
3. Why the hetero‑drug aspect matters for patents
* Chemical uniqueness – The presence of hetero atoms (especially N in a pyrimidine) creates a distinctive electronic and steric environment that is not found in simple aromatics.
* Patent claims often hinge on hetero‑atom substitution patterns – small changes in N‑substituents can generate new chemical space and new claims.
* Biological relevance – Hetero atoms directly participate in H‑bonding with the capsid protein; this is often highlighted in the claims’ “mechanism‑of‑action” language.
* Broader freedom‑to‑operate – By filing multiple patents on various hetero‑substituted analogues, the applicant covers a large swath of potential competitors.
---
4. Practical take‑aways for researchers or companies
| Question | Answer |
|----------|--------|
| Can I synthesize an analogue with a different hetero ring? | The patents cover a broad set of hetero‑aromatics (pyrimidine, pyrazine, etc.). You’d need to check if a particular substitution pattern falls outside the scope of the claims. |
| Is the sodium salt patented? | Yes – US20190102861A1 and WO20190102861A1 specifically claim the sodium salt. |
| What about formulation patents? | US20200046171A1 covers the depot microsphere technology;